Skip to main content

Table 1 Clinicopathological data of the EAC-patients included in the study

From: HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma

   

HER2 expression

P value

Total

Negative

Positive

a) Demographic and pathological results of the cohort

 SEX

female

38

10.5%

34

89.5%

4

10.5%

0.333

male

324

89.5%

284

87.70%

40

12.3%

 

 Age group

<  65 yrs

195

53.8%

167

85.5%

28

14.5%

0.062

>  65 yrs

167

46.1%

151

90.4%

16

9.6%

 

 Tumor stage

pT1

33

9.1%

26

80.0%

7

20.0%

0.038

pT2

30

8.3%

28

93.9%

2

6.1%

 

pT3

287

79.2%

251

87.7%

35

12.3%

 

pT4

11

3.0%

11

100.0%

0

0.0%

 

 Lymph node metastasis

pN0

138

38.0%

113

82.5%

24

17.5%

0.02

pN+

224

62.0%

204

91.1%

20

8.9%

 

 Grading

G1/2

152

61.8%

126

82.9%

26

17.1%

0.009

G3/4

94

38.2%

89

94.7%

5

5.4%

 

 UICC

I

50

13.8%

39

78.8%

11

21.2%

0.039

II

53

14.6%

47

89.1%

6

10.9%

 

III

169

46.7%

147

86.9%

22

13.1%

 

IV

89

24.6%

84

94.7%

5

5.3%

 

b) Cross-table analysis of the patient cohort

 

Hazard ratio

95% confidence interval

P value

Lower

Upper

 SEX (female vs. male)

1.718

0.977

3.023

0.06

 Age group (<  65 vs. >  65 yrs)

1.194

0.914

1.559

0.193

 pT (pT1/2 vs. pT3/4)

1.331

0.982

1.804

0.065

 pN (pN0 vs. pN+)

0.937

0.77

1.139

0.513

 UICC (Stage I/II vs. III/IV)

1.975

1.559

2.503

0

 HER2 expression (neg. vs. pos.)

0.628

0.401

0.983

0.042